Evidence map›Paper›PMID 42379777›Full record

ArticleIn vivo (Athens, Greece)

Impact of CD73/CD155 Expression on Survival in Resected Epithelial Pleural Mesothelioma: A Retrospective Single-center Study.

Yusuke Nabe, Yasuhiro Fujita, Teppei Hashimoto, Kanji Tanaka, Takehiko Manabe, Katsuma Yoshimatsu, Yukiko Nemoto, Natsumasa Nishizawa, Rintaro Oyama, Yohei Honda and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yusuke NabeSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; usk-nabe@kmf.biglobe.ne.jp.
Yasuhiro FujitaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Teppei HashimotoSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Kanji TanakaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Takehiko ManabeSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Katsuma YoshimatsuSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Yukiko NemotoSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Natsumasa NishizawaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Rintaro OyamaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Yohei HondaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Masataka MoriSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Hiroki MatsumiyaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Masatoshi KanayamaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Akihiro TairaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Masaru TakenakaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Koji KurodaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Shohei ShimajiriDepartment of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Fumihiro TanakaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimWhile CD73 and CD155 are implicated in immune evasion and tumor progression, their roles in pleural mesothelioma (PM) remain unclear. Therefore, we investigated the association between CD73 and CD155 expression in resected epithelial PM specimens and explored their impact on 5-year progression-free survival (PFS) and 5-year overall survival (OS). PATIENTS AND

methodsThis single-center retrospective study enrolled 43 patients with epithelial PM who underwent curative-intent surgery, with/without chemotherapy and immune checkpoint inhibitor (ICI) treatment, between January 2013 and December 2020. HALO-AI pathology software was used to quantify CD73 and CD155 expression following immunohistochemical staining. Cutoff values for CD73/CD155 positivity were determined using receiver operating characteristic curves. Patients were categorized into CD73+/CD155+ and non-CD73+/CD155+ groups, and survival outcomes were analyzed using Kaplan-Meier curves and Cox proportional hazards regression.

resultsAmong 35 cases, patients with CD73+/CD155+ tumors exhibited significantly improved 5-year PFS compared with those with non-CD73+/CD155+ tumors (64.8%

conclusionCD155 may serve as a poor prognostic factor in mesothelioma and represents the first immunohistochemical evaluation of this marker. Although CD73 and CD155 co-expression were initially predicted to indicate poor prognosis, findings were unexpected, likely due to inability to establish an optimal cutoff value given variations in patient demographics, disease stage, and treatment approaches.

Indexed as

5'-NucleotidaseMesothelioma, MalignantPleural NeoplasmsAgedBiomarkers, TumorFemaleGPI-Linked ProteinsHumansMaleMiddle AgedPrognosisRetrospective Studies5'-NucleotidaseBiomarkers, TumorGPI-Linked ProteinsNT5E protein, humanadjuvantCD155 antigenCD73 antigenchemotherapydisease progressionimmunotherapypleural mesotheliomapleurodesisprognostic biomarkerssurvival analysis

Identifiers

PMID42379777
PMCPMC13322047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.